{"groups":[{"description":"Received dalteparin 5000 units daily postop, patients with metastatic disease.","id":"FG000","title":"Interventional (Dalteparin, Metastatic)"},{"description":"Received dalteparin 5000 units daily postop, patients with primary sarcomas.","id":"FG001","title":"Interventional (Dalteparin, Sarcoma)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"25"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 65 participants enrolled into the trial. 15 participants did not meet entry criteria and were excluded.","recruitmentDetails":"Recruitment Period: July 2006 - December 2010"}